Oslo, 3 March 2016 - Navamedic ASA (OSE: NAVA) the Norwegian medtech and pharmaceutical marketing- and distribution company today announced an expanded cooperation agreement with German pharmaceutical manufacturer, Pohl-Boskamp, for distribution of Nitrolingual® Pumpspray in the Nordic markets.
Nitrolingual® Pumpspray is an oral spray of nitroglycerine used for relief or prevention of sudden attacks of chest pain associated with angina pectoris caused by heart disease. Annual sales of Nitrolingual® in the Nordic markets are expected to be around NOK 8 million.
"Our cooperation with Pohl-Boskamp has proven highly successful. We are delighted to add Nitrolingual to our portfolio and expect it to be very well-received in the Nordic markets. The expansion is in line with the growth strategy we are pursuing in this region, based on high-performing products and working with strong suppliers," said Tom Rönnlund, CEO of Navamedic.
Navamedic has distributed several Pohl-Boskamp products in the Nordic markets since 2014, including NYDA® head lice treatment and GeloRevoice® throat lozenges, which are now available at more than 1,400 pharmacies across the Nordic region.
"We are pleased to have a solid partner in Navamedic. We look forward to continuing the collaboration and working together to bring new treatment products into the Nordic markets," added Bodo Heibrock, Senior Director of International Sales at Pohl-Boskamp.
For further information, please contact:
Tom Rönnlund, CEO Navamedic
Telephone +46 727 320 321
Navamedic ASA is a Norwegian medtech and pharmaceutical products company, delivering products to hospitals, pharmacies and health products stores in the Nordic and Benelux markets. The Group's Medtech business has developed and is currently introducing the next generation digital urine meter Sippi ®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).
Pohl-Boskamp is a privately owned business active in the international pharmaceutical market for 175 years with commercialized products in more than 45 countries. Through close collaboration with its partners abroad, Pohl-Boskamp focuses on developing and marketing products that positively impact patients' quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders and dermatology.